Reynolds Vuse E-Cigarette Market Share Increases, Juul Ranking 2rd

Business by 2FIRSTS.ai
Nov.20.2023
Reynolds Vuse E-Cigarette Market Share Increases, Juul Ranking 2rd
According to Journalnow, Reynolds Tobacco's Vuse e-cigarette market share increases to 42.1%, surpassing Juul's 24.4%.

According to a recent report by Journalnow, Reynolds Tobacco's e-cigarette brand Vuse has seen a slight increase in market share, rising to 42.1%. This surpasses the second-ranked Juul, which has maintained a market share of 24.4%.

 

Meanwhile, the market share of NJoy, a subsidiary of Altria Group and ranked number three, has not significantly increased, remaining at 2.5%.

 

In addition, Altria and British American Tobacco warn that the prevalence of illegal synthetic nicotine e-cigarettes is increasing in the American market. According to estimates by both companies, these illicit synthetic e-cigarette products represent approximately half of the domestic market share in the United States.

 

According to reports, this report covers a four-week period from the previous report until November 4th. Nielsen's data for this report mostly comes from major retail chains.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Observation|VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation
2Firsts Observation|VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation
2Firsts observed at Stockholm Arlanda Airport that British American Tobacco’s VELO positions the airport environment as a core marketing scenario, deploying large-format LED displays, a full flavour matrix, and clear nicotine-strength segmentation. The brand also features an instructional “How to Use VELO” section and multi-pack sales strategy, showcasing its systematic merchandising capabilities in the Nordic travel-retail channel.
Nov.19 by 2FIRSTS.ai
From Partnership to Acquisition: Why KT&G Is Betting on the Global Nicotine Pouch Market
From Partnership to Acquisition: Why KT&G Is Betting on the Global Nicotine Pouch Market
As global competition in the nicotine pouch market accelerates, Korea’s tobacco major KT&G has moved with a “Partnership + Acquisition” strategy, teaming up with Altria to acquire Nordic pouch maker Another Snus Factory (brand “LOOP”). Why deploy capital now, and why take this route? Drawing on company disclosures, regulatory monitoring and on-site observations from InterTabac Dortmund, 2Firsts analyzes KT&G’s strategic calculus and the signals behind this move.
Nov.05
FDA Rolls Out Online PMTA Platform, a Move That 2Firsts Analysts Say Could Pull Grey-Market Products Toward Formal Compliance
FDA Rolls Out Online PMTA Platform, a Move That 2Firsts Analysts Say Could Pull Grey-Market Products Toward Formal Compliance
FDA’s launch of a web-based PMTA system signals faster reviews and, 2Firsts experts say, a possible inflection point for the U.S. e-cigarette market’s shift out of the grey zone.
Dec.04
Exclusive: Altria Confirms FDA Grants Marketing Authorization to on! PLUS, Ending More Than a Year of PMTA Review
Exclusive: Altria Confirms FDA Grants Marketing Authorization to on! PLUS, Ending More Than a Year of PMTA Review
Altria on December 19 confirmed that six on! PLUS nicotine pouch products had received U.S. FDA marketing authorization, ending a PMTA review lasting more than a year after the company moved ahead with launch plans before clearance.
Regulations
Dec.20
Japan Tobacco launches limited-edition Ploom AURA color “Bronze Royal,” priced at about $27
Japan Tobacco launches limited-edition Ploom AURA color “Bronze Royal,” priced at about $27
Japan Tobacco (JT) announced that Ploom AURA has added a second limited-edition colorway, “Bronze Royal,” which will be available in limited quantities through official channels starting November 11, priced at approximately $27.3.
Nov.12 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai